Investor relations

NGM: MEDFIN

Invest in Medicortex

01

Significant medical need

Traumatic brain injury and concussion are areas with a significant need for faster, simpler and more accessible diagnostics. Today it can be difficult to assess the extent of an injury early, especially in milder brain injuries where symptoms are not always clear immediately after the injury.

Medicortex is developing a diagnostic test designed to identify brain injuries using biomarkers in easily accessible samples such as saliva and urine. The goal is to give healthcare providers more practical decision support in acute situations and contribute to earlier detection, better prioritisation and better-informed care decisions.

Over time, such a test could become important in many settings where rapid assessment of brain injury matters, such as emergency care, sports, defence and clinical studies.

Illustration of brain injury diagnostics and emergency care

02

Technology with broad application

Medicortex's technology is based on biomarkers that can be identified in easily accessible samples such as saliva and urine. This creates the conditions for a diagnostic test that can be simpler to use than more resource-intensive methods and, over time, made available in more care settings.

The same lateral-flow format can be adapted to new biomarkers, which makes the platform scalable beyond a single test. Production builds on established, cost-efficient manufacturing methods, and the sample types allow testing without specialised equipment or trained laboratory staff.

This broad potential application means Medicortex is not addressing a single care scenario, but a wider need for accessible diagnostics for traumatic brain injury and concussion.

Illustration of diagnostics for healthcare, sports and defence

03

Research-based platform with patent protection

Medicortex has built a research-based platform focused on biomarkers for diagnosing traumatic brain injury and concussion. The company combines neurobiological research with clinical development, providing a clear scientific foundation for its continued work on diagnostic tests.

The company has conducted clinical studies in collaboration with Finnish hospitals and has built a patent portfolio covering biomarkers, diagnostics and related technology. This strengthens its ability to protect its innovations and develop a commercial position in brain injury diagnostics.

A research-based, patent-protected platform can give Medicortex better opportunities to create long-term value as the technology is further developed, validated and brought closer to market.

Illustration of research, clinical development and patent protection